Company Overview
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Revenue has grown at a 57.5% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $27.47M (+195.7% YoY); net profit $-26.60M.
- Trailing 12 Months Year-on-year growth — revenue +166.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 57.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 57.50% |
| 1 Year: | 166.70% |
Stock Price Performance
| 1 Year: | +23.46% |
| 6 Months: | +232.23% |
| 3 Months: | +3.16% |
| 1 Month: | +10.62% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.01 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 57.5% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CUE Cue Biopharma, Inc. PHARMA | 30.00 | -1.02 | $217.93M | 0.00% | -92.46% | - | 57.50% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 172.00K | 449.00K | 370.00K | 1.05M | 984.00K | 900.00K | 1.07M | 704.00K | 1.55M | 2.74M | 2.40M | 1.00M | 26.00K | 68.00K | 187.00K | 1.38M | 2.10M | 1.72M | 2.66M | 3.34M | 421.00K | 2.95M | 2.15M | 5.69M |
| Operating Income | -3.35M | -4.41M | -5.03M | -7.52M | -7.47M | -12.76M | -11.43M | -9.23M | -7.09M | -12.99M | -10.94M | -10.13M | -12.52M | -10.30M | -13.02M | -14.24M | -13.09M | -11.03M | -13.38M | -13.52M | -11.42M | -12.67M | -10.38M | -8.81M | -12.30M | -8.63M | -7.59M | -5.35M |
| Net Income | -3.35M | -4.41M | -5.03M | -7.52M | -7.30M | -12.56M | -11.27M | -9.52M | -6.99M | -12.82M | -10.83M | -10.03M | -12.51M | -10.28M | -12.99M | -14.26M | -13.21M | -10.96M | -13.11M | -13.19M | -11.01M | -12.35M | -10.17M | -8.66M | -12.26M | -8.48M | -7.45M | -5.18M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.41 | -0.44 | -0.37 | -0.31 | -0.29 | -0.29 | -0.24 | -0.25 | -0.20 | -0.17 | -4.95 | -0.09 | -0.07 | -1.08 |
| R&D Expense | 2.46M | 3.42M | 4.00M | 5.82M | 5.41M | 10.31M | 8.35M | 6.87M | 5.30M | 9.91M | 8.12M | 7.52M | 9.82M | 8.76M | 11.29M | 10.08M | 9.59M | 7.57M | 9.39M | 10.65M | 9.87M | 10.20M | 9.53M | 9.38M | 8.55M | 7.91M | 4.75M | 6.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.14M | 3.46M | 3.15M | 14.94M | 1.25M | 5.49M | 9.29M | 27.47M |
| Operating Income | -23.23M | -38.70M | -36.77M | -45.04M | -43.71M | -53.23M | -52.15M | -41.50M | -26.55M |
| Net Income | -23.23M | -38.98M | -36.70M | -44.78M | -44.16M | -53.01M | -50.73M | -40.67M | -26.60M |
| Diluted EPS | - | - | - | - | -1.41 | -1.49 | -1.11 | -0.72 | -0.28 |
| R&D Expense | 18.90M | 28.54M | 27.49M | 33.55M | 41.35M | 38.58M | 40.80M | 36.30M | 37.74M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 66.95M | 45.36M | 71.61M | 99.53M | 83.40M | 91.28M | 61.53M | 32.19M | 42.21M |
| Total Equity | 15.17M | 61.61M | 33.97M | 54.58M | 78.91M | 65.49M | 65.68M | 37.09M | 17.50M | 26.43M |
| Cash & Equivalents | - | - | 20.80M | 44.29M | 74.87M | 64.37M | 51.61M | 48.51M | 22.46M | 27.14M |
| Long Term Debt | - | - | - | - | - | 0 | 8.04M | 4.20M | 0 | - |
| Total Liabilities | - | 5.35M | 11.39M | 17.02M | 20.62M | 17.91M | 25.60M | 24.45M | 14.69M | 15.78M |
| Current Liabilities | - | 5.35M | 6.22M | 11.66M | 16.32M | 12.79M | 11.55M | 17.08M | 13.69M | 13.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.14M | -26.41M | -30.80M | -32.49M | -38.84M | -41.81M | -39.96M | -36.33M | -21.69M |
| Investing Cash Flow | -1.20M | -20.35M | 3.45M | 4.46M | 9.11M | -24.61M | 25.00M | 32.00K | 75.00K |
| Financing Cash Flow | 62.00M | 4.18M | 50.79M | 58.61M | 19.23M | 53.66M | 11.86M | 10.24M | 26.29M |
| Capital Expenditure | -1.03M | -1.85M | -46.35K | -595.26K | -913.04K | -171.00K | -0 | -66.00K | -177.00K |
| Free Cash Flow | -13.17M | -28.27M | -30.84M | -33.09M | -39.75M | -41.98M | -39.96M | -36.40M | -21.86M |
| Share Buybacks | - | - | 91.03K | 271.05K | 750.13K | 200.00K | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -3,386.7% | -1,063.2% | -1,428.0% | -292.6% | -4,275.1% | -949.9% | -446.9% | -96.7% |
| Net Margin % | - | -3,411.5% | -1,061.2% | -1,419.8% | -295.6% | -4,257.8% | -924.1% | -438.0% | -96.9% |
| ROE % | -37.7% | -114.7% | -67.2% | -56.8% | -67.4% | -80.7% | -136.8% | -232.4% | -100.6% |
| ROCE % | -37.7% | -98.9% | -61.3% | -54.1% | -61.9% | -66.8% | -117.3% | -224.3% | -92.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bleichroeder LP | 5.10% | 370.68K | $13.73M |
| 2 | Driehaus Capital Management, LLC | 4.02% | 292.14K | $10.82M |
| 3 | Vanguard Capital Management LLC | 2.23% | 161.70K | $5.99M |
| 4 | Ikarian Capital, LLC | 1.44% | 104.36K | $3.87M |
| 5 | Tetragon Partners GP Ltd. | 1.29% | 93.82K | $3.48M |
| 6 | Stempoint Capital LP | 0.92% | 67.00K | $2.48M |
| 7 | Blackrock Inc. | 0.80% | 57.81K | $2.14M |
| 8 | Adar1 Capital Management, LLC | 0.76% | 55.19K | $2.04M |
| 9 | Lion Point Capital, LP | 0.73% | 52.93K | $1.96M |
| 10 | Squadron Capital Management LLC | 0.69% | 50.00K | $1.85M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CUE
$CUE stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNS3VUT3hEYlJrRmR0TWp1dWNVLW1nTVpYbS1FSzgxQjZuRGF5T1UtMHdHVkJEY3VyMW1mVkhYUFNudnZhSjdiR19tRUFDVGVpOU9BNkRLN0x2T0lJMzRXOUVqQkhOU3BPNUdNZGpEbWgwVGFqVmxGUjE2N3FpOHVmZDN1bXRpb1dsRFZ6Vj…
Cue Biopharma (NASDAQ: CUE) exec's tax sell-to-cover after equity grant - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQd1prWDhBRlVPUEc0ZGJma0gwTWNaWVlnVWRIckdmLWxIUzM5MGZ6dk5LSHB6cGJoaUd5c0xFa1VSVTNqOXRtZlo3d2I5NXAwNUw3N3l5REZUZllCcmxTWXR5c0dnR2tteHlaZXRlUjh5Q0ZicElQbnE4X2FtQzFRbGtnWUpXLVVRaUx4Tl…
CUE - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE9pWTkwZDBQTmJnSE5jOEJpSXR0aXVmTF9nRzJSYW9KcVlqUlpxbUNEanVVNnppTVZ3MmdOVUJFRzRZME9B?oc=5" target="_blank">CUE</a> <font color="#6f6f6f">Finviz</font>…
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPMVJ3dFJqLU5oMjdRLUlIUFUtTzNrMEZ2TjU4MFFyeURTWmRRWE5zVTVfVUkzaEVmN01KTG4tTHFBR1FHVUhkd0dNYkVqb2tVSmxkbFB3V3Nxc3FVc2NSOGxzNTVuWVRIalh6aTRKNFlYZXlTckdqZWx0Z01ZakQybHFqOHE4V0JoU2xCNm…
Cue Biopharma, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPZDIyS1pjODg3UVpNZGpIUlVmWjU1cWt0aTJTSlV2NzBSZTBJcnRNQ0czS3hWT1hqSkRoY0ZWNEgtZHdJT05UV0pZUzJaUE00YUdxbldQWmxOZUM2TFdaVERsVnhJcThKLWZvbHFpcm5CaGVLUEs3N0dVekhONG1mV3dMNTB1cjNWZE1uYX…
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQR09FT2FQMnc0cDJYRXRxR2lOcmVfMkNPRFgzbE95RlMzWmVqVVZGeVdQYXZvX0JOYjU3RXpPVkdhaG5uV1JVTC10OGt2Z3Z5cUN1MXI3WXFrSUJOdUZ6WEVLNUc2dktac3cyU21KTFhlR2xuRG5CWXhLenV1Q3hBVzBWSzBJcEszUEdNUX…
CUE — Frequently Asked Questions
What is the current share price of Cue Biopharma, Inc. (CUE)?
As of 2026-09-19 21:16 PDT, Cue Biopharma, Inc. (CUE) trades at $30.00 on NasdaqCM. Its 52-week range is $5.31 to $36.78.
What is the market capitalisation of CUE?
Cue Biopharma, Inc. (CUE) has a market capitalisation of $217.93M on NasdaqCM.
What is the P/E ratio of CUE?
CUE trades at a trailing price-to-earnings (P/E) ratio of -1.02. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 69.00.
Is CUE a good stock to buy?
This page provides a data-driven analysis of Cue Biopharma, Inc. (CUE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.